SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 781.97 |
| Enterprise Value ($M) | 732.49 |
| Book Value ($M) | 345.82 |
| Book Value / Share | 5.68 |
| Price / Book | 2.26 |
| NCAV ($M) | 310.19 |
| NCAV / Share | 5.10 |
| Price / NCAV | 2.52 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.50 |
| Return on Assets (ROA) | -0.37 |
| Return on Equity (ROE) | -0.40 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.26 |
| Current Ratio | 10.26 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 410.03 |
| Assets | 445.67 |
| Liabilities | 99.84 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Redmile Group, LLC | 5.30 | 18.57 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 8.00 | 27.63 | |
| 13G/A | First Light Asset Management, LLC | 3.21 | -46.94 | |
| 13G/A | Blue Owl Capital Holdings LP | 4.94 | 0.00 | |
| 13G/A | Laurion Capital Management LP | 0.00 | -100.00 | |
| 13G | Paradigm Biocapital Advisors LP | 5.03 | ||
| 13G/A | Deep Track Capital, LP | 9.60 | 85.21 | |
| 13G/A | Third Rock Ventures III, L.P. | 3.60 | 0.00 | |
| 13G | Vanguard Group Inc | 5.12 | ||
| 13G/A | Fmr Llc | 6.62 | -9.78 | |
| 13G | BlackRock, Inc. | 8.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 148,929 | 598,977 | 24.86 | |
| 77,126 | 366,044 | 21.07 | |
| 41,953 | 183,650 | 22.84 | |
| 62,296 | 265,322 | 23.48 | |
| 56,914 | 269,586 | 21.11 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PGEN – Precigen, Inc. | PHAT – Phathom Pharmaceuticals, Inc. |
| PHVS – Pharvaris N.V. | PMVP – PMV Pharmaceuticals, Inc. |
| PRAX – Praxis Precision Medicines, Inc. |
Financial data and stock pages provided by
Fintel.io